Cargando…
Genetic screening for neovascular AMD: cost effective…not so quick
The following is a response to Brown and colleagues (Int J Retin Vitr 1:19, 2015), who analyzed the cost effectiveness of genetic screening for neovascular AMD in Category 3 (intermediate). As explained in this letter, it is premature to propose that genetic screening is cost effective in this setti...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5088460/ https://www.ncbi.nlm.nih.gov/pubmed/27847617 http://dx.doi.org/10.1186/s40942-015-0024-5 |